Sequenom Inc. (Nasdaq: SQNM) announced that Harry Hixson Jr., Ph.D., will retire as CEO effective as of the company's 2014 annual meeting on June 10. William Welch, the company's current president and chief operating officer, will assume the role of CEO immediately upon Hixson's retirement.
Hixson will continue to serve as the chairman of the company's board of directors following his retirement and following his re-election to the board of directors by the company's stockholders at the annual meeting. Hixson has served as chairman since 2003 and as CEO since Sept. 2009. The board will also nominate Welch for election to the company's Board of Directors on June 10.
Welch joined the company in January 2011 as senior vice president of diagnostics and was appointed president and COO in Dec. 2012. Prior to joining Sequenom, Welch was a consultant to molecular diagnostic companies in the personalized medicine sector. Previously, Welch served as senior vice president and chief commercial officer at Monogram Biosciences. Before joining Monogram, he held management roles at La Jolla Pharmaceutical Co., Dade Behring MicroScan and Abbott Laboratories.
Sequenom also announced that Dirk van den Boom, Ph.D., will be promoted to chief scientific and strategy officer as of the annual meeting. Van den Boom has recently served as Sequenom's executive vice president of research and development, and chief scientific officer. He joined Sequenom in 1998 at the company's Hamburg office, subsequently serving in various management roles of increasing responsibility within the R&D department.
Lastly, Paul Maier, CFO since 2009, will retire effective June 10, and will serve as a consultant to the company following his retirement. Carolyn Beaver, current vice president and chief accounting officer, will assume the role of CFO immediately upon Maier's retirement as CFO.